Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 8, 2016, Pages 1525-1533

  Oe, Yuji ^a   Hayashi, Sakiko ^b   Fushima, Tomofumi ^b   Sato, Emiko ^a,b   Kisu, Kiyomi ^a   Sato, Hiroshi ^a,b   Ito, Sadayoshi ^a   Takahashi, Nobuyuki ^a,b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

cardiovascular diseases; diabetic nephropathy; factor Xa; inflammation; prognosis

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; CYTOKINE; EDOXABAN; MESSENGER RNA; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; THROMBOPLASTIN; ANTIINFLAMMATORY AGENT; AUTACOID; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INS2 PROTEIN, MOUSE; INSULIN; NOS3 PROTEIN, MOUSE; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENDOTHELIUM CELL; GENE; GLOMERULUS; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROFIBROTIC GENE; PROINFLAMMATORY GENE; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; CELL LINE; DEFICIENCY; DIABETIC NEPHROPATHIES; DISEASE MODEL; DRUG EFFECTS; GENETICS; GENOTYPE; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD COAGULATION; CELL LINE; CYTOKINES; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FACTOR XA; FACTOR XA INHIBITORS; GENOTYPE; HUMANS; INFLAMMATION MEDIATORS; INSULIN; KIDNEY GLOMERULUS; MACROPHAGES; MALE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; PODOCYTES; PYRIDINES; RECEPTOR, PAR-2; SIGNAL TRANSDUCTION; THIAZOLES; UP-REGULATION;

EID: 84973532017     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.307883     Document Type: Article

References (49)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-2047. doi: 10. 1001/jama. 298. 17. 2038
2. Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis. 2012;59:75-83. doi: 10. 1053/j. ajkd. 2011. 09. 017
3. Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2012;12:CD004136. doi: 10. 1002/14651858. CD004136. pub3
4. Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012;55:566-578. doi: 10. 1007/s00125-011-2398-8
5. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yuzawa Y, Atkinson MA, Johnson RJ, Croker B. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol. 2007;18:539-550. doi: 10. 1681/ ASN. 2006050459
6. Wang CH, Li F, Hiller S, Kim HS, Maeda N, Smithies O, Takahashi N. A modest decrease in endothelial NOS in mice comparable to that associated with human NOS3 variants exacerbates diabetic nephropathy. Proc Natl Acad Sci USA. 2011;108:2070-2075. doi: 10. 1073/ pnas. 1018766108
7. Li F, Wang CH, Wang JG, Thai T, Boysen G, Xu L, Turner AL, Wolberg AS, Mackman N, Maeda N, Takahashi N. Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet. J Thromb Haemost. 2010;8:2122-2132. doi: 10. 1111/j. 1538-7836. 2010. 03976. x
8. Schaffner F, Ruf W. Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost. 2008;34:147-153. doi: 10. 1055/s-2008-1079254
9. Erlich JH, Boyle EM, Labriola J, Kovacich JC, Santucci RA, Fearns C, Morgan EN, Yun W, Luther T, Kojikawa O, Martin TR, Pohlman TH, Verrier ED, Mackman N. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol. 2000;157:1849-1862
10. Owens AP 3rd, Passam FH, Antoniak S, et al. Monocyte tissue factordependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest. 2012;122:558-568. doi: 10. 1172/JCI58969
11. Badeanlou L, Furlan-Freguia C, Yang G, Ruf W, Samad F. Tissue factorprotease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation. Nat Med. 2011;17:1490-1497. doi: 10. 1038/ nm. 2461
12. Krupiczojc MA, Scotton CJ, Chambers RC. Coagulation signalling following tissue injury: focus on the role of factor Xa. Int J Biochem Cell Biol. 2008;40:1228-1237. doi: 10. 1016/j. biocel. 2008. 02. 026
13. Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med. 2008;14:429-440. doi: 10. 1016/j. molmed. 2008. 08. 001
14. Rothmeier AS, Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol. 2012;34:133-149. doi: 10. 1007/ s00281-011-0289-1
15. Frank RD, Schabbauer G, Holscher T, Sato Y, Tencati M, Pawlinski R, Mackman N. The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia-reperfusion injury. J Thromb Haemost. 2005;3:531-540. doi: 10. 1111/j. 1538-7836. 2005. 01188. x
16. Nomura K, Liu N, Nagai K, Hasegawa T, Kobayashi I, Nogaki F, Tanaka M, Arai H, Fukatsu A, Kita T, Ono T. Roles of coagulation pathway and factor Xa in rat mesangioproliferative glomerulonephritis. Lab Invest. 2007;87:150-160. doi: 10. 1038/labinvest. 3700502
17. Chung H, Ramachandran R, Hollenberg MD, Muruve DA. Proteinaseactivated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-β receptor signaling pathways contributes to renal fibrosis. J Biol Chem. 2013;288:37319-37331. doi: 10. 1074/jbc. M113. 492793
18. Moussa L, Apostolopoulos J, Davenport P, Tchongue J, Tipping PG. Protease-activated receptor-2 augments experimental crescentic glomerulonephritis. Am J Pathol. 2007;171:800-808. doi: 10. 2353/ ajpath. 2007. 061155
19. Pejler G, Lunderius C, Tomasini-Johansson B. Macrophages synthesize factor X and secrete factor X/Xa-containing prothrombinase activity into the surrounding medium. Thromb Haemost. 2000;84:429-435
20. Zhao P, Metcalf M, Bunnett NW. Biased signaling of protease-activated receptors. Front Endocrinol (Lausanne). 2014;5:67. doi: 10. 3389/ fendo. 2014. 00067
21. Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014;124:2333-2340. doi: 10. 1172/ JCI72271
22. Shahzad K, Bock F, Dong W, et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int. 2015;87:74-84. doi: 10. 1038/ki. 2014. 271
23. Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, Cullere X, Eckfeldt JH, Doria A, Mayadas TN, Warram JH, Krolewski AS. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol. 2012;23:507-515. doi: 10. 1681/ASN. 2011060627
24. Sayyed SG, Ryu M, Kulkarni OP, Schmid H, Lichtnekert J, Grüner S, Green L, Mattei P, Hartmann G, Anders HJ. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int. 2011;80:68-78. doi: 10. 1038/ki. 2011. 102
25. Scotton CJ, Krupiczojc MA, Königshoff M, Mercer PF, Lee YC, Kaminski N, Morser J, Post JM, Maher TM, Nicholson AG, Moffatt JD, Laurent GJ, Derian CK, Eickelberg O, Chambers RC. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest. 2009;119:2550-2563. doi: 10. 1172/JCI33288
26. Shinagawa K, Martin JA, Ploplis VA, Castellino FJ. Coagulation factor Xa modulates airway remodeling in a murine model of asthma. Am J Respir Crit Care Med. 2007;175:136-143. doi: 10. 1164/rccm. 200608-1097OC
27. Wilcox JN, Noguchi S, Casanova J. Extrahepatic synthesis of factor VII in human atherosclerotic vessels. Arterioscler Thromb Vasc Biol. 2003;23:136-141
28. Parahuleva MS, Maj R, Hölschermann H, Parviz B, Abdallah Y, Erdogan A, Tillmanns H, Kanse SM. Regulation of monocyte/macrophage function by factor VII activating protease (FSAP). Atherosclerosis. 2013;230:365-372. doi: 10. 1016/j. atherosclerosis. 2013. 08. 007
29. Sumi A, Yamanaka-Hanada N, Bai F, Makino T, Mizukami H, Ono T. Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice. Biol Pharm Bull. 2011;34:824-830
30. Yiu WH, Wong DW, Chan LY, Leung JC, Chan KW, Lan HY, Lai KN, Tang SC. Tissue kallikrein mediates pro-inflammatory pathways and activation of protease-activated receptor-4 in proximal tubular epithelial cells. PLoS One. 2014;9:e88894. doi: 10. 1371/journal. pone. 0088894
31. Lee EY, Chung CH, Khoury CC, Yeo TK, Pyagay PE, Wang A, Chen S. The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGFbeta, increases podocyte motility and albumin permeability. Am J Physiol Renal Physiol. 2009;297:F85-F94. doi: 10. 1152/ajprenal. 90642. 2008
32. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int. 2002;62:929-939. doi: 10. 1046/j. 1523-1755. 2002. 00520. x
33. Cheng H, Fan X, Guan Y, Moeckel GW, Zent R, Harris RC. Distinct roles for basal and induced COX-2 in podocyte injury. J Am Soc Nephrol. 2009;20:1953-1962. doi: 10. 1681/ASN. 2009010039
34. Cheng H, Fan X, Moeckel GW, Harris RC. Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression. J Am Soc Nephrol. 2011;22:1240-1251. doi: 10. 1681/ ASN. 2010111149
35. Madhusudhan T, Wang H, Straub BK, et al. Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood. 2012;119:874-883. doi: 10. 1182/blood-2011-07-365973
36. Pan SL, Tao KY, Guh JH, Sun HL, Huang DY, Chang YL, Teng CM. The p38 mitogen-activated protein kinase pathway plays a critical role in PAR2-induced endothelial IL-8 production and leukocyte adhesion. Shock. 2008;30:496-502. doi: 10. 1097/SHK. 0b013e3181673233
37. Shpacovitch VM, Brzoska T, Buddenkotte J, Stroh C, Sommerhoff CP, Ansel JC, Schulze-Osthoff K, Bunnett NW, Luger TA, Steinhoff M. Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappaB in human dermal microvascular endothelial cells. J Invest Dermatol. 2002;118:380-385. doi: 10. 1046/j. 0022-202x. 2001. 01658. x
38. Muth H, Kreis I, Zimmermann R, Tillmanns H, Hölschermann H. Differential gene expression in activated monocyte-derived macrophages following binding of factor VIIa to tissue factor. Thromb Haemost. 2005;94:1028-1034. doi: 10. 1160/TH05-01-0002
39. Daubie V, Cauwenberghs S, Senden NH, Pochet R, Lindhout T, Buurman WA, Heemskerk JW. Factor Xa and thrombin evoke additive calcium and proinflammatory responses in endothelial cells subjected to coagulation. Biochim Biophys Acta. 2006;1763:860-869. doi: 10. 1016/j. bbamcr. 2006. 04. 010
40. López-Farré AJ, Rodriguez-Sierra P, Modrego J, Segura A, Martín-Palacios N, Saiz AM, Zamorano-León JJ, Duarte J, Serrano J, Moñux G. Effects of factor Xa on the expression of proteins in femoral arteries from type 2 diabetic patients. Br J Clin Pharmacol. 2014;78:1366-1377. doi: 10. 1111/bcp. 12469
41. Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG. Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med. 2000;191:455-462
42. Sevastos J, Kennedy SE, Davis DR, Sam M, Peake PW, Charlesworth JA, Mackman N, Erlich JH. Tissue factor deficiency and PAR-1 deficiency are protective against renal ischemia reperfusion injury. Blood. 2007;109:577-583. doi: 10. 1182/blood-2006-03-008870
43. Wang H, Madhusudhan T, He T, Hummel B, Schmidt S, Vinnikov IA, Shahzad K, Kashif M, Muller-Krebs S, Schwenger V, Bierhaus A, Rudofsky G, Nawroth PP, Isermann B. Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy. Blood. 2011;117:5231-5242. doi: 10. 1182/blood-2010-10-314773
44. Wronkowitz N, Görgens SW, Romacho T, Villalobos LA, Sánchez-Ferrer CF, Peiró C, Sell H, Eckel J. Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochim Biophys Acta. 2014;1842:1613-1621. doi: 10. 1016/j. bbadis. 2014. 06. 004
45. Kumar Vr S, Darisipudi MN, Steiger S, et al. Cathepsin s cleavage of protease-activated receptor-2 on endothelial cells promotes microvascular diabetes complications. J Am Soc Nephrol. 2016;27(6): 1635-1649. doi: 10. 1681/ASN. 2015020208
46. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891. doi: 10. 1056/NEJMoa1009638
47. Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104. doi: 10. 1056/ NEJMoa1310907
48. Nobakht N, Kamgar M, Rastogi A, Schrier RW. Limitations of angiotensin inhibition. Nat Rev Nephrol. 2011;7:356-359. doi: 10. 1038/ nrneph. 2011. 29
49. Schmidlin F, Amadesi S, Dabbagh K, Lewis DE, Knott P, Bunnett NW, Gater PR, Geppetti P, Bertrand C, Stevens ME. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol. 2002;169:5315-5321